{"id":"W4408979751","doi":"10.1016/s1556-0864(25)00328-4","title":"133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital","funders":"EMD Serono; Genentech; Sumitomo Dainippon Pharma Oncology; Sun Pharma; Chinese Society of Clinical Oncology; PharmaMar; European Society for Medical Oncology; Coherus Biosciences; Seagen; Pfizer; Biogen; Incyte; International Association for the Study of Lung Cancer; BeiGene; Mirati Therapeutics; Les Laboratories Pierre Fabre; AstraZeneca; Associazione Italiana di Oncologia Medica; Novocure; Ipsen; Jazz Pharmaceuticals; Revolution Medicines; Regeneron Pharmaceuticals; G1 Therapeutics; Jounce Therapeutics; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Sanofi; Cilag; Cardinal Health; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; First line treatment; Internal medicine; Lung; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516286,0.001942216,0.003206872,0.000442789,0.0003737967,0.001427749,0.001241398,0.001623727,0.008172748],"category_scores_gemma":[0.00129512,0.0007346194,0.002579325,0.0004032791,0.001120134,0.001076786,0.0005152649,0.004805332,0.001620178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001209796,"about_ca_system_score_gemma":0.001670249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001359566,"about_ca_topic_score_gemma":0.003164727,"domain_scores_codex":[0.9994252,0.0002622313,0.0000214916,0.00009687516,0.00004282246,0.0001515558],"domain_scores_gemma":[0.9993718,0.0001255514,0.0001171221,0.00005777574,0.0000347661,0.0002929562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9585865,0.009165307,0.0006518147,0.0004267022,0.001359928,0.00002814532,0.00003464427,0.0006655675,0.004128688,0.0002309925,0.002122799,0.02259884],"study_design_scores_gemma":[0.9405286,0.05610223,0.001328401,0.00001835113,0.0005050328,0.00002257343,0.00001421233,0.0003472696,0.0003196624,0.0001389087,0.0006635236,0.00001136956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799863,0.003595315,0.001069103,0.001177468,0.0008642563,0.005438804,0.003030813,0.0003000803,0.004537899],"genre_scores_gemma":[0.9721162,0.00283452,0.003067843,0.002438079,0.0005810541,0.007887508,0.004425467,0.0001055256,0.006543845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008172748,"threshold_uncertainty_score":0.02734059,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0267252023477661,"score_gpt":0.41932747852948,"score_spread":0.3926022761817139,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}